CDC’s Risk-Benefit Assessment for New COVID-19 Vaccines Flawed: Experts

Experts claim that a U.S. government new analysis of COVID-19 vaccination benefits and risks exaggerates the benefits and downplays the risks.

The U.S. Centers for Disease Control and Prevention conducted a recent risk-benefit assessment for the new bivalent vaccinations. The assessment was performed for adolescents aged between 12-17.

The CDC Estimate One million doses of this drug over six months could prevent up to 136 hospitalizations and zero to one death. It used outdated, non-peer-reviewed CDC effectiveness estimates. Study Only data was used to analyze adult data. Hospitalization rates are hospitalizations for which COVID-19 was used as an additional reason rather than a primary reason.

Megan Wallace, a CDC representative presented the assessment. The assessment was presented by Megan Wallace, a CDC official. She said that the combination of the potential benefits and the harms to adolescents using the hospitalization rates based on the sensitive analyses makes it clear that we can expect between 31-136 hospitalizations and nine-to-40 ICU admissions. One death is also possible.

The second version also included incidental hospitalizations, which reduced the number of hospitalizations to 17 instead of 75.

Both versions stated that there was no myocarditis among young people who had received a bivalent Booster in a single CDC-run surveillance programme. The system gave adolescents less than 100,000 doses, and young men could have been exposed to up to 62 cases per million doses.

Myocarditis (or inflammation of the heart) is a side effect from COVID-19 vaccines. This is more common in young men.

The presentation was criticized by critics.

Allison Krug (an epidemiologist) stated to The Epoch Times, “It was.” “definitely flawed”.

The problem is the hospitalization rate COVID-NETThese rates don’t include children’s rates or outpatient medical encounters, as some researchers believe. You have doneSearching for myocarditis cases.

Krug stated that risk-benefit analyses were a marketing strategy to increase vaccine adoption. It is not fair for people to attempt to assess the risks and benefits. However, it fails to consider the most durable protection available–immunity from prior infection. This protection is almost universal today.

Krug did a risk-benefit assessment of Moderna vaccines and Pfizer vaccines. adolescent boys For more information, please visit: College booster mandates.

Dr. Tracy Hoeg is another epidemiologist Described She described the assessment as “top-level incompetence” because the CDC tried to justify giving bivalent boosters for children.

Wallace and the CDC did not respond to our requests for comment.

There are no clinical data

The U.S. authorities had to rely upon observational data for bivalent boosters from Moderna and Pfizer, which were approved and recommended in fall 2022. Six months later, there was still no evidence of clinical effectiveness. Mice data It was used to justify the approval of vaccines.

Moderna and Pfizer have not yet responded to inquiries about when data from their trials might be available.

Pfizer and BioNTech, its partner Announcement It announced on March 1, that it had requested U.S. regulators to approve a bivalent booster vaccine for children younger than 5 years. Based on data from trials, the company claimed that data showed that the bivalent produced more neutralizing antibodies and that its safety profile was similar to the original vaccine.

Multiple members of the Advisory Committee on Immunization Practices were concerned about the absence of trial data when the CDC presented their risk-benefit analysis. They were also asked if authorities should switch to an annual booster.

“I would love to see a study that said, ‘okay. You’ve just received one bivalent vaccine. What’s the benefit? What is the benefit? And how long will it last?” Dr. Camille Kotton said, one of the advisors.

Kotton and Dr. Matthew Daley both said they would like to see trials of vaccines. However, Daley suggested a comparison of coadministration of influenza vaccines and COVID-19 vaccines as opposed to administering each vaccine separately.

Daley stated that “we would learn a lot more about immunogenicity, safety,” and added “that might be useful for this conversation.”

Inflated Death Toll

Officials repeatedly cited the fact that COVID-19 has caused the deaths of many children as a reason to recommend vaccines for kids, despite the lack of data on the effectiveness of the initial shots.

The CDC has Inflated death data for children Before and after Refused requests To make a correction.

Dr. Sara Oliver, a CDC official, Data on deaths presented A slide was shown at the meeting. It stated that 1,489 COVID-19-related deaths had occurred in children six months to seventeen years old, but the total also included children 0 to five months.

Oliver didn’t respond to our request for comment.

Kelley Krohnert is a Georgia mother who repeatedly fact-checks false CDC claims. She noted that the slide also included deaths in which COVID-19 wasn’t the underlying cause, but a contributing factor.

“Yet more evidence of why I am so great!” Argument She stated that CDC functions more like a marketing/sales agency than a healthcare agency on Twitter.

New Myocarditis Study

After Canadian researchers had completed their research, the presentations took place. reported A higher incidence of myocarditis and pericarditis after Moderna or Pfizer vaccinations, especially after dose 2 of the primary series.

The researchers analyzed health records from Quebec and found that there was a 15% higher incidence than expected within 7 Days of a Second Dose for males aged 16-17, and a 7.6 Times higher incidence for males 12-15.

Out of 77 incidents, 63 were among males while 51 were after taking dose two. Only three adolescents were admitted to the emergency room, while 34 others were taken to hospital.

Myocarditis can cause long-term health problems such as Heart failure and deathOther research has also shown this.